Key Developments: HeartWare International Inc (HTWR.O)
95.05USD
21 May 2013
$-2.40 (-2.46%)
$99.19
$97.80
$98.07
$94.44
258,520
242,786
$99.68
$74.77
Latest Key Developments (Source: Significant Developments)
HeartWare International Inc Announces Closing Of Public Offering Of Common Stock
HeartWare International Inc announced the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on December 9, 2010. This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock to cover over-allotments. HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses. J.P. Morgan Securities LLC acted as the sole book-running manager for the offering. Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and Lazard Capital Markets LLC acted as co-managers of the offering. Perella Weinberg Partners served as independent capital markets advisor to HeartWare on this offering. Full Article
HeartWare International Inc Announces Closing of Public Offering of Common Stock
HeartWare International Inc announced the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on December 9, 2010. This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock to cover over-allotments. HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses. J.P. Morgan Securities LLC acted as the sole book-running manager for the offering. Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and Lazard Capital Markets LLC acted as co-managers of the offering. Perella Weinberg Partners served as independent capital markets advisor to HeartWare on this offering. Full Article
HeartWare International Inc Announces Pricing of Public Offering of Common Stock
HeartWare International Inc announced the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any. HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and Lazard Capital Markets LLC are acting as co-managers of the offering. Perella Weinberg Partners served as independent capital markets advisor to HeartWare on this offering. Full Article
HeartWare International Inc Announces Public Offering Of Common Stock
HeartWare International Inc announced its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any. HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. The offering does not require the prior approval of HeartWare's stockholders under the requirements of the Australian Stock Exchange. Full Article
HeartWare International Inc Not To Pay FY 2012 Dividend
HeartWare International, Inc. announced that the Directors do not recommend that a dividend relating to fiscal 2012 be paid. Full Article
HeartWare International Inc Issues Q4, FY 2012 Revenue Guidance
HeartWare International Inc announced that it expects total revenues for the fourth quarter of 2012 will be approximately $32 million, bringing expected fiscal 2012 revenues to approximately $110 million. Full Article
HeartWare International Inc Receives FDA Approval For HeartWare Ventricular Assist System As A Bridge To Heart Transplantation For Patients with Advanced Heart Failure
HeartWare International Inc announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. The HeartWare Ventricular Assist System features the HVAD pump, a small full-support circulatory assist device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HVAD pump, with sintered inflow cannula, weighs approximately 5 ounces and displaces a volume of approximately 50 milliliters. The HeartWare System is intended for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Full Article
HeartWare International Inc Announces Issuance Of New Shares
HeartWare International Inc announced that it has issued as 7,500 shares of common stock at an issue price of AUD 38.50 per share for a total consideration of AUD 288,750.00. Full Article
HeartWare International, Inc. Recommends Not To Pay Interim Dividend
HeartWare International, Inc. announced that no dividend was paid during the period ended June 30, 2012 and the Directors do not recommend that a dividend relating to the interim period ended June 30, 2012 be paid. As such, there is no franking or applicable record date. Full Article
HeartWare International, Inc. Completes Acquisition Of World Heart Corporation
HeartWare International, Inc. announced the closing of the acquisition of World Heart Corporation following the approval of the transaction by World Heart stockholders. Under the terms of the merger agreement, HeartWare acquired all of the outstanding voting securities of World Heart for merger consideration of approximately $8,000,000 in HeartWare common stock, as calculated in accordance with the terms of the merger agreement. Each share of World Heart common stock has been converted into the right to receive 0.003 shares of HeartWare common stock. The boards of directors of both companies previously approved the transaction, which was approved by World Heart's stockholders at a special stockholders meeting. HeartWare stockholder approval was not required. Following the transaction and the issuance of approximately 83,000 new shares of HeartWare common stock to World Heart stockholders, HeartWare will have approximately 14,275,000 shares of common stock outstanding. Full Article
HeartWare loss smaller than expected; shares rise
- Medical device maker HeartWare International Inc reported a smaller-than-expected first-quarter loss after sales of its heart pump soared 62 percent, sending its shares up 8 percent in after-market trading.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
